Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVIDâ„¢ to Help Combat COVID-19
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1, The additional 3.7
Let's personalize your content